Click here for slides on this topic


DPP-4

Abbreviation for dipeptidyl peptidase-4. Also referred to as dipeptidyl peptidase-IV (DPP-IV).


The following content matched the glossary term: DPP-4

Treating the Patient With Type 2 Diabetes and Renal Impairment – References

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Key Take-Home Messages

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Proteinuria

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Metformin

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Pharmacologic Treatment for Type 2 Diabetes

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Hypoglycemia

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Treatment Adjustment for Renal Impairment

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Case Discussion Renal Impairment

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Medical History Physical Exam

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: DPP-4 Slides Found: 176
DPP: Study Questions
DPP: Patients
DPP: Treatment Protocol
DPP: Incidence of Type 2 Diabetes
DPP: Reduction in Diabetes Incidence
DPP: Fasting Plasma Glucsose and HbAlc
DPP: Weight Loss and Physical Activity
Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance
Type 2 Diabetes Prevention Studies
US DPP Incidence of Type 2 Diabetes With Different Interventions
Diabetes Incidence Rates by Ethnicity With Different Interventions
DPP: Weight Loss and Activity
DPP: Study Questions
DPP: Patients
DPP: Treatment Protocol
DPP: Incidence of Type 2 Diabetes
DPP: Reduction in Diabetes Incidence
DPP: Fasting Plasma Glucsose and HbAlc
DPP: Weight Loss and Physical Activity
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
Finnish Diabetes Prevention Study: Sustained Benefit of Lifestyle Intervention
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Effects of Sitagliptin vs Glipizide on Body Weight in Type 2 Diabetes
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Vildagliptin: Percentage of Patients Achieving A1C <7%
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
DPP: Incidence of Type 2 Diabetes
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Alogliptin Monotherapy: A1C
Alogliptin and Glyburide Combination Therapy: A1C
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Alogliptin Study 010, Primary Endpoint: Change in A1C at 26 Weeks
Alogliptin Study 010, Secondary Efficacy Endpoint at Week 26: Hyperglycemia
Alogliptin Study 010: Exploratory Endpoints of Alogliptin Therapy vs Placebo
Alogliptin Study 010: Safety
Vildagliptin vs Metformin: A1C
Saxagliptin for Treatment of Type 2 Diabetes: Design
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in A1C from Baseline to Week 24
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results A1C Reduction
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
DPP and DPPOS: Timeline
DPP: A Look Back
DPPOS Bridge: Year 4
DPPOS Maintenance: Years 5-10
Long-Term Use of Metformin in DPPOS
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Medication Adherence
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Weight Loss
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Waist Circumference
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Achievement of ≥5% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Achievement of ≥10% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Effect of Adherence on Body Weight, Waist Circumference
Long-Term Use of Metformin in DPPOS: Results Including DPPOS Open-Label Treatment—Metformin Adherence
Long-Term Use of Metformin in DPPOS: Results During DPP—Safety & Tolerability
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
Long-Term Use of Metformin in DPPOS: Results During DPP—Average Hemoglobin, Hematocrit Levels Over Time
DPPOS Substudy: Effect of Regression from Prediabetes to NGR on Diabetes Risk
DPPOS Substudy: NGR Status and Risk Reduction
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Design
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Diabetes Guidelines Pharmacologic Therapy for Older Adults | NDEI
Connection Between Type 2 Diabetes and Heart Failure PPT | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
No Heart Failure Hospitalization Risk With Sitagliptin in TECOS | NDEI
No Increased Risk of HF Hospitalization, CV Death With Sitagliptin TECOS | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI
TECOS No HF Hospitalization Risk With Sitagliptin Treatment Diabetes | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI